PAX-8 (MRQ-50) Mouse Monoclonal Antibody
Specialties: Anatomic Pathology
Detection of PAX-8 by immunohistochemistry (IHC) with PAX-8 (MRQ-50) Mouse Monoclonal Antibody may be used to aid in the diagnosis of ovarian serous carcinomas, clear cell renal cell carcinomas, and thyroid carcinomas.
PAX-8 is a member of the paired box (PAX) family of lineage-specific transcription factors, which play critical roles in the formation of tissues and organs during embryonic development. PAX-8 is expressed during embryonic development of the Müllerian tract (female genital tract), kidney, and thyroid.1 PAX-8 is normally expressed in female genital tract epithelium, renal tubular epithelium, and thyroid follicular epithelium.1 PAX-8 expression is also seen in most ovarian serous carcinomas, clear cell renal cell carcinomas, and thyroid carcinomas.2-6 PAX-8 contains an N-terminal domain that is highly conserved among the PAX family of transcription factors and a C-terminal DNA binding domain that is specific to PAX-8. The PAX-8 (MRQ-50) antibody binds to the N-terminal of the PAX-8 protein and thus has shown cross-reactivity with PAX-5 and PAX-6 proteins, which label some lymphocytes and neuroendocrine cells, respectively.5 PAX-8 immunohistochemistry shows a nuclear pattern of staining.
- Ozcan, Ayhan et al. "PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study." Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc vol. 24,6 (2011): 751-64.
- Nonaka, Daisuke et al. "Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms." Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc vol. 21,2 (2008): 192-200.
- Nonaka, Daisuke et al. "Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas." The American journal of surgical pathology vol. 32,10 (2008): 1566-71.
- Laury, Anna R et al. "A comprehensive analysis of PAX8 expression in human epithelial tumors." The American journal of surgical pathology vol. 35,6 (2011): 816-26.
- Ordóñez, Nelson G."Value of PAX 8 immunostaining in tumor diagnosis: a review and update." Advances in anatomic pathology vol. 19,3 (2012): 140-51.
- Mentrikoski, Mark J et al. "Immunohistochemical distinction of renal cell carcinoma from other carcinomas with clear-cell histomorphology: utility of CD10 and CA-125 in addition to PAX-2, PAX-8, RCCma, and adipophilin." Applied immunohistochemistry & molecular morphology : AIMM vol. 22,9 (2014): 635-41.
- Nadji M, Morales AR. Immunoperoxidase, part I: the techniques and its pitfalls. Lab Med 1983;14:767
- Omata M, Liew CT, Ashcavai M, Peters RL. Nonimmunologic binding of horseradish peroxidase to hepatitis B surface antigen. A possible source of error in immunohistochemistry. Am J Clin Pathol. 1980 May; 73(5):626-32. doi: 10.1093/ajcp/73.5.626. PMID: 6155065.
Specifications
- Reactivity: paraffin
- Control: Ovarian carcinoma (non-mucinous carcinoma) (Nuclear); Thyroid carcinoma (Nuclear); Renal cell carcinoma (Nuclear)
- Dilution Range: 1:50-1:200 *
Package Inserts
IFU
- IVD Rev. 5.0 (CMC36321050)
Have a different keycode?
Click Here
Learn how to obtain your SDS
Ordering Information
For in vitro diagnostic (IVD) use in USA
| 25.0 mL predilute ready-to-use | 363M-10 |
| 0.1 mL concentrate | 363M-14 |
| 0.5 mL concentrate | 363M-15 |
| 1.0 mL concentrate | 363M-16 |
| 1.0 mL predilute ready-to-use | 363M-17 |
| 7.0 mL predilute ready-to-use | 363M-18 |
For in vitro diagnostic (IVD) use in Canada
| 25.0 mL predilute ready-to-use | 363M-10 |
| 0.1 mL concentrate | 363M-14 |
| 0.5 mL concentrate | 363M-15 |
| 1.0 mL concentrate | 363M-16 |
| 1.0 mL predilute ready-to-use | 363M-17 |
| 7.0 mL predilute ready-to-use | 363M-18 |
For in vitro diagnostic (IVD) use in Europe
| 25.0 mL predilute ready-to-use | 363M-10 |
| 0.1 mL concentrate | 363M-14 |
| 0.5 mL concentrate | 363M-15 |
| 1.0 mL concentrate | 363M-16 |
| 1.0 mL predilute ready-to-use | 363M-17 |
| 7.0 mL predilute ready-to-use | 363M-18 |
For research use only (RUO) in Japan
| 25.0 mL predilute ready-to-use (RUO) | 363M-10-RUO |
| 0.1 mL concentrate (RUO) | 363M-14-RUO |
| 0.5 mL concentrate (RUO) | 363M-15-RUO |
| 1.0 mL concentrate (RUO) | 363M-16-RUO |
| 1.0 mL predilute ready-to-use (RUO) | 363M-17-RUO |
| 7.0 mL predilute ready-to-use (RUO) | 363M-18-RUO |
To request information on this product in additional countries, please click the button below.
